Clinical Trials are medical research involving human subjects. Clinical Trials evaluate medical, surgical, or behavioral interventions to determine if a novel treatment is safe and effective. There are four phases of Clinical Trial testing used to test the new treatment, determine the most effective dosage, and ensure the adverse effects do not outweigh the medical benefits.
What if your lab could perform exome sequencing with the same sensitivity and efficiency of targeted sequencing? The new integrated QIAseq Human Exome TR Insights solution from QIAGEN delive...
Today's presentation will cover the following topics from the perspective of a NYC based Laboratory: What have we learned year to date about CoV-2 and specifically how diagnostic testing...
As many parts of the northern hemisphere move into the colder months and indoors, SARS CoV-2 has begun a second infection wave that has exceeded the first surge of cases in many global regio...
Cell-free DNA (cfDNA) is a key analyte for liquid biopsy samples. Due to extremely low concentration and high degree of fragmentation, the extraction of cfDNA is technically challenging. Her...
Testing volumes need to increase by orders of magnitude in order to restore communities back to normality. This workshop focuses on solutions that equip laboratories to participate in expand...
In 2012, the Choosing Wisely initiative was commenced by the ABIM with numerous societies putting forward lists of overused tests or procedures. The Choosing Wisely movement has spread to nu...
The nuclear proliferation biomarker Ki-67 has multiple potential roles in breast and other cancers, both as a prognostic but also predictive marker. However, several studies have shown that...
Point-of-care testing (POCT) is destined to play a much greater role in chronic disease diagnosis and management. Advanced POCT systems are being developed to deliver less costly and more ac...
Clinical Laboratories have the opportunity to support value based health care by aligning with organizational strategies that focus on population health and creating meaningful insights usin...
The opioid crisis has put significant strain on the healthcare system and resources, including the clinical laboratory which has seen significant increases in requests for urine drug screeni...
Patient laboratory test results are significantly over-represented in electronic medical records, but significantly under-utilized in research. An important application of laboratory data is...
Cases of traumatic brain injury (TBI) have been steadily rising over the past decade with most common causes of injury observed among participants in contact sports, combat military personne...
Date: November 2, 2020 Time: 8:00am PST. Rapid and accurate microbial diagnostic information can change treatment courses and outcomes for patients inflicted with infections. The limitation...
Precision oncology continues to evolve as additional clinically relevant biomarkers are identified. The challenges facing both diagnostic laboratories and clinicians include not only the abi...
Precision oncology continues to evolve as additional clinically relevant biomarkers are identified. The challenges facing the clinical researchers include not only the ability to add additio...
High grade serous ovarian cancer is characterized by genomic instability, with ~50% of advanced tumors harboring homologous recombination repair (HRR) pathway deficiency (HRD). HRD results i...
High grade serous ovarian cancer is characterized by genomic instability, with ~50% of advanced tumors harboring homologous recombination repair (HRR) pathway deficiency (HRD). HRD results i...
There is an expanding list of therapeutically relevant biomarkers for non-small cell lung cancer (NSCLC), and molecular profiling at diagnosis is paramount. Tissue attrition in scaling tradi...
There is an expanding list of therapeutically relevant biomarkers for non-small cell lung cancer (NSCLC), and molecular profiling at diagnosis is paramount. Tissue attrition in scaling tradi...
Date: September 16, 2020 Time: 7:00am (PDT), 10:00am (EDT) Of the 15 million patients admitted to US based hospitals with medical, non-surgical illnesses, 8 million possess inherent risk of...
DATE: October 09, 2020 TIME: 08:00am PT Traditional culture techniques, as the primary diagnostic tool for infectious diseases, are coming under scrutiny for failing to universally detect in...
DATE: October 8, 2020 TIME: 1:00pm PDT Microsatellite instability (MSI) has evolved as a marker of potential hereditary cancer risk and is now a tissue agnostic immune biomarker with a broad...
Cancer is a multifactorial disease, and its genesis and progression are extremely complex. The scope of precision oncology is rapidly expanding to address previously undruggable targets. The...
Date: October 7, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Recently the FDA approved the BD Onclarity HPV assay as a test to identify HPV high-risk genotypes in addition to HPV 16 and 18 i.e.,...
What if your lab could perform exome sequencing with the same sensitivity and efficiency of targeted sequencing? The new integrated QIAseq Human Exome TR Insights solution from QIAGEN delive...
Today's presentation will cover the following topics from the perspective of a NYC based Laboratory: What have we learned year to date about CoV-2 and specifically how diagnostic testing...
As many parts of the northern hemisphere move into the colder months and indoors, SARS CoV-2 has begun a second infection wave that has exceeded the first surge of cases in many global regio...
Cell-free DNA (cfDNA) is a key analyte for liquid biopsy samples. Due to extremely low concentration and high degree of fragmentation, the extraction of cfDNA is technically challenging. Her...
Testing volumes need to increase by orders of magnitude in order to restore communities back to normality. This workshop focuses on solutions that equip laboratories to participate in expand...
In 2012, the Choosing Wisely initiative was commenced by the ABIM with numerous societies putting forward lists of overused tests or procedures. The Choosing Wisely movement has spread to nu...
The nuclear proliferation biomarker Ki-67 has multiple potential roles in breast and other cancers, both as a prognostic but also predictive marker. However, several studies have shown that...
Point-of-care testing (POCT) is destined to play a much greater role in chronic disease diagnosis and management. Advanced POCT systems are being developed to deliver less costly and more ac...
Clinical Laboratories have the opportunity to support value based health care by aligning with organizational strategies that focus on population health and creating meaningful insights usin...
The opioid crisis has put significant strain on the healthcare system and resources, including the clinical laboratory which has seen significant increases in requests for urine drug screeni...
Patient laboratory test results are significantly over-represented in electronic medical records, but significantly under-utilized in research. An important application of laboratory data is...
Cases of traumatic brain injury (TBI) have been steadily rising over the past decade with most common causes of injury observed among participants in contact sports, combat military personne...
Date: November 2, 2020 Time: 8:00am PST. Rapid and accurate microbial diagnostic information can change treatment courses and outcomes for patients inflicted with infections. The limitation...
Precision oncology continues to evolve as additional clinically relevant biomarkers are identified. The challenges facing both diagnostic laboratories and clinicians include not only the abi...
Precision oncology continues to evolve as additional clinically relevant biomarkers are identified. The challenges facing the clinical researchers include not only the ability to add additio...
High grade serous ovarian cancer is characterized by genomic instability, with ~50% of advanced tumors harboring homologous recombination repair (HRR) pathway deficiency (HRD). HRD results i...
High grade serous ovarian cancer is characterized by genomic instability, with ~50% of advanced tumors harboring homologous recombination repair (HRR) pathway deficiency (HRD). HRD results i...
There is an expanding list of therapeutically relevant biomarkers for non-small cell lung cancer (NSCLC), and molecular profiling at diagnosis is paramount. Tissue attrition in scaling tradi...
There is an expanding list of therapeutically relevant biomarkers for non-small cell lung cancer (NSCLC), and molecular profiling at diagnosis is paramount. Tissue attrition in scaling tradi...
Date: September 16, 2020 Time: 7:00am (PDT), 10:00am (EDT) Of the 15 million patients admitted to US based hospitals with medical, non-surgical illnesses, 8 million possess inherent risk of...
DATE: October 09, 2020 TIME: 08:00am PT Traditional culture techniques, as the primary diagnostic tool for infectious diseases, are coming under scrutiny for failing to universally detect in...
DATE: October 8, 2020 TIME: 1:00pm PDT Microsatellite instability (MSI) has evolved as a marker of potential hereditary cancer risk and is now a tissue agnostic immune biomarker with a broad...
Cancer is a multifactorial disease, and its genesis and progression are extremely complex. The scope of precision oncology is rapidly expanding to address previously undruggable targets. The...
Date: October 7, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Recently the FDA approved the BD Onclarity HPV assay as a test to identify HPV high-risk genotypes in addition to HPV 16 and 18 i.e.,...
Opens in a new windowOpens an external siteOpens an external site in a new window
Follow
